MEI Pharma Inc (MEIP)
2.875
-0.04
(-1.54%)
USD |
NASDAQ |
Nov 18, 16:00
2.89
+0.02
(+0.52%)
After-Hours: 20:00
Price Chart
Key Stats
| Price and Performance | |
|---|---|
| Market Cap | 19.26M |
| 52 Week High (Daily) | Upgrade |
| 52 Week Low (Daily) | Upgrade |
| All-Time High (Daily) | Upgrade |
| Year to Date Total Returns (Daily) | Upgrade |
| 1 Month Total Returns (Daily) | Upgrade |
| 1 Year Total Returns (Daily) | -52.14% |
| Valuation | |
| PE Ratio | 1.082 |
| PE Ratio (Forward) | Upgrade |
| PS Ratio | 0.1827 |
| Price to Book Value | 0.5831 |
| EV to EBITDA | Upgrade |
| Dividend | |
|---|---|
| Dividend | -- |
| Dividend Yield (Forward) | Upgrade |
| Financials | |
| Revenue (5 Year Growth) | Upgrade |
| Revenue (Quarterly YoY Growth) | Upgrade |
| EPS Diluted (5 Year Growth) | Upgrade |
| EPS Diluted (Quarterly YoY Growth) | Upgrade |
| Debt to Equity Ratio | -- |
| Return on Equity | Upgrade |
| Return on Assets | Upgrade |
| Risk | |
| Beta (5Y) | Upgrade |
| Max Drawdown (5Y) | 96.19% |
Profile
| MEI Pharma Inc is focused on the clinical development of novel therapies for cancer. The company's clinical drug candidate includes Pracinostat, an orally available histone deacetylase inhibitor for the treatment of patients with acute myeloid leukemia and myelodysplastic syndrome. Its clinical development portfolio also includes Zandelisib, an oral inhibitor of phosphatidylinositide 3-kinase delta for the treatment of patients with recurrent chronic lymphocytic leukemia or follicular non-Hodgkin's lymphoma; and ME-344, an isoflavone-based mitochondrial inhibitor for the treatment of HER2-negative breast cancer and Pracinostat, an oral histone deacetylase inhibitor. Geographically, all the business activities function through the region of the United States. |
| URL | https://www.meipharma.com |
| Investor Relations URL | https://www.meipharma.com/investors/ |
| HQ State/Province | California |
| Sector | Health Care |
| Industry | Biotechnology |
| Equity Style | Small Cap/Value |
| Next Earnings Release | Feb. 13, 2025 (est.) |
| Last Earnings Release | Nov. 12, 2024 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | Nov. 16, 2023 |
Ratings
Profile
| MEI Pharma Inc is focused on the clinical development of novel therapies for cancer. The company's clinical drug candidate includes Pracinostat, an orally available histone deacetylase inhibitor for the treatment of patients with acute myeloid leukemia and myelodysplastic syndrome. Its clinical development portfolio also includes Zandelisib, an oral inhibitor of phosphatidylinositide 3-kinase delta for the treatment of patients with recurrent chronic lymphocytic leukemia or follicular non-Hodgkin's lymphoma; and ME-344, an isoflavone-based mitochondrial inhibitor for the treatment of HER2-negative breast cancer and Pracinostat, an oral histone deacetylase inhibitor. Geographically, all the business activities function through the region of the United States. |
| URL | https://www.meipharma.com |
| Investor Relations URL | https://www.meipharma.com/investors/ |
| HQ State/Province | California |
| Sector | Health Care |
| Industry | Biotechnology |
| Equity Style | Small Cap/Value |
| Next Earnings Release | Feb. 13, 2025 (est.) |
| Last Earnings Release | Nov. 12, 2024 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | Nov. 16, 2023 |